美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Vericiguat	Tablet	II (Paddle)	75	0.01 N HCl, pH 2.0	900	5, 10, 15, 20 and 30	2022/07/07
Verteporfin	Injectable			Develop a method to characterize in vitro release.			2014/08/14
Vibegron	Tablet			Refer to FDA's Dissolution Guidance, 2018			2023/02/09
Vigabatrin	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Vilazodone HCl	Tablet	II (Paddle)	60	0.1% v/v Glacial acetic acid solution (pH 3.1)	1000	10, 15, 20, 30 and 45	2014/08/14
Viloxazine HCl	Capsule (Extended Release)	II (Paddle) with sinker	50	pH 6.8 Phosphate Buffer	900	1, 2, 4, 6, 8, 10, 12 and 16 hours	2022/07/07
Vismodegib	Capsule	II (Paddle)	75	0.01 N HCl with 1.0% sodium lauryl sulfate (SLS)	900	10, 15, 20, 30 and 45	2015/05/28
Voclosporin	Capsule	II (Paddle)	75	0.75% of Polyoxyl 40 hydrogenated castor oil in sodium acetate buffer (22mM), pH 4.5	900	10, 20, 30, 45 and 60	2023/02/09
Vorapaxar Sulfate	Tablet	II (Paddle)	50	41 mM Na2HPO4, 1.5% Citric Acid, pH 3.0 ± 0.5	900	5, 10, 20, 30, 45 and 60	2015/12/24
Voriconazole	Suspension	II (Paddle)	50	0.1 N HCl	900	10, 20, 30 and 45	2007/01/03
Voriconazole	Tablet	II (Paddle)	50	0.1 N HCl	900	10, 20, 30 and 45	2008/11/25
Vorinostat	Capsule			Develop a dissolution method			2023/09/15
Vortioxetine HBr	Tablet	II (Paddle)	50	0.1 N HCl	900	10, 15, 20, 30 and 45	2015/05/28
Voxelotor	Tablet	II (Paddle)	75	50 mM phosphate buffer (pH 6.8) with 2% sodium lauryl sulfate (SLS)	900	5, 10, 20, 30 and 45	2022/07/28
Voxelotor	Tablet, for Suspension	II (Paddle)	75	50 mM phosphate buffer (pH 6.8) with 2% sodium lauryl sulfate (SLS)	900	5, 10, 15, 20 and 30	2022/07/28
Warfarin Sodium	Tablet			Develop a dissolution method			2024/01/03
Zafirlukast	Tablet	II (Paddle)	50	1% w/v Aqueous Sodium Dodecyl Sulfate	1000	10. 30, 30 and 45	2007/10/09
Zalcitabine	Tablet			Develop a dissolution method			2024/01/03
Zaleplon	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Zidovudine	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02